ETHK Labs Reclassifies B-Soft Deal as Major Transaction After Listing Rules Review

IVD Medical Holding Limited ( (HK:1931) ) has provided an announcement.

ETHK Labs Inc. has clarified that its previously announced acquisition of shares and voting rights in Chinese technology company B-Soft should be treated as a major transaction under Hong Kong listing rules, rather than a discloseable transaction. Because the deal structure grants ETHK Labs control over B-Soft’s board and consolidates B-Soft’s financial results, the company must now apply 100% of the target’s assets, revenue and profit for transaction-size tests.

A reassessment in strict compliance with Rule 14.28 showed that one or more percentage ratios for the deal exceed 25% but remain below 100%, triggering the more stringent major transaction requirements. The board acknowledged earlier non-compliance with rules on issuing a circular and obtaining shareholder approval, attributing it to misinterpretation amid a complex cross-border deal, and plans to convene an extraordinary general meeting to seek shareholder ratification and regularize the acquisition and related voting-rights entrustment.

The most recent analyst rating on (HK:1931) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.

More about IVD Medical Holding Limited

ETHK Labs Inc., formerly known as IVD Medical Holding Limited, is a Cayman Islands–incorporated company listed in Hong Kong that has expanded from its medical and diagnostics roots into broader technology-related investments. The group is now focusing on strategic acquisitions, including gaining control over Chinese technology firm B-Soft, to deepen its presence in the digital and healthcare technology space.

Average Trading Volume: 4,698,216

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.95B

Find detailed analytics on 1931 stock on TipRanks’ Stock Analysis page.